SCHEMBL26485641

SCHEMBL26485641

C#CCNc1nc(=O)n(-c2cnccn2)c2cc(C(F)(F)F)cc(OC)c12

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAT2A P31153 6/20 0.39
▸ SCN9A Q15858 3/20 0.34
▸ PDE2A O00408 3/20 0.33
▸ PDE10A Q9Y233 3/20 0.33
▸ PDE6D O43924 2/20 0.33
▸ PDE6A P16499 2/20 0.33
▸ PDE6G P18545 2/20 0.33
▸ PDE6B P35913 2/20 0.33
▸ PDE6C P51160 2/20 0.33
▸ PDE6H Q13956 2/20 0.33
▸ LMNA P02545 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.31
▸ SLC6A9 P48067 1/20 0.31
▸ BUB1 O43683 1/20 0.31
▸ GRM1 Q13255 1/20 0.31
▸ ABCG2 Q9UNQ0 1/20 0.31
▸ CYP3A4 P08684 1/20 0.30
▸ CYP3A5 P20815 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31026800 1.00 MAT2A (0.39) MAT2ASCN9APDE2APDE10APDE6D
SCHEMBL30420838 0.88 MAT2A (0.41) MAT2APDE10AKDM4E
SCHEMBL26093155 0.88 MAT2A (0.41) MAT2APDE10AKDM4E
SCHEMBL26091783 0.87 MAT2A (0.41) MAT2APDE2APDE10APDE6DPDE6A
SCHEMBL30420438 0.87 MAT2A (0.41) MAT2APDE2APDE10APDE6DPDE6A
SCHEMBL26485128 0.86 MAT2A (0.50) MAT2ASCN9APDE10ALMNAL3MBTL1
SCHEMBL30418873 0.86 MAT2A (0.50) MAT2ASCN9APDE10ALMNAL3MBTL1
SCHEMBL30420280 0.85 MAT2A (0.35) MAT2ASCN9APDE2APDE10APDE6D
SCHEMBL26091386 0.85 MAT2A (0.35) MAT2ASCN9APDE2APDE10APDE6D
SCHEMBL30419914 0.83 MAT2A (0.40) MAT2ASCN9APDE2APDE10APDE6D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11999713-B2 Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof INSILICO MEDICINE IP LIMITED (HK) 2024-06-04 — — US disclosed
US-20240132465-A1 METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF INSILICO MEDICINE LTD. (CN) 2024-04-25 — — US disclosed
WO-2023066283-A1 METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITORS AND USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2023-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999713-B2 Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof MAT2A, MAT2B, MAT1A MAT2A 1/4885SCN9A 3737/4885PDE2A 555/4885
US-20240132465-A1 METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITORS AND USES THEREOF MAT2A, MAT2B, MAT1A MAT2A 1/4885SCN9A 3737/4885PDE2A 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback